Mak Sze Man Jennifer, Wong Wai Yee, Chung Hoi Sze, Chung Pui Wah, Kong Grace Wing Shan, Li Tin Chiu, Cheung Lai Ping
Assisted Reproduction Technology Unit, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Assisted Reproduction Technology Unit, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.
Reprod Biomed Online. 2017 Mar;34(3):258-266. doi: 10.1016/j.rbmo.2016.11.014. Epub 2016 Dec 16.
Luteinizing hormone (LH) is crucial for the development of follicular growth and oocyte maturation, especially in the management of poor ovarian responders (PORs). This study presents the results of a prospective double-blinded randomized study to compare the effect of mid-follicular phase recombinant LH (rLH) supplementation with urinary human chorionic gonadotrophin (uHCG) supplementation when using a fixed gonadotrophin-releasing hormone (GnRH) antagonist protocol in IVF cycles. A total of 49 women with poor ovarian response (POR) according to the Bologna criteria were recruited. This study showed no statistically significant difference in cycle cancellation rates, numbers of oocytes retrieved per cycle initiated, fertilization rates, the numbers of embryos obtained per cycle initiated, implantation, clinical pregnancy and live birth rates, although the live birth rate per cycle initiated in the uHCG group (29.2%) was 3.6 times that of the rLH group (8.0%). Further studies are required to verify if uHCG supplementation produces better clinical outcomes compared with rLH in women with POR.
促黄体生成素（LH）对卵泡生长发育和卵母细胞成熟至关重要，尤其在卵巢反应不良者（POR）的治疗中。本研究展示了一项前瞻性双盲随机研究的结果，该研究在体外受精（IVF）周期中使用固定剂量的促性腺激素释放激素（GnRH）拮抗剂方案时，比较卵泡中期补充重组LH（rLH）与补充尿源性人绒毛膜促性腺激素（uHCG）的效果。根据博洛尼亚标准，共招募了49例卵巢反应不良（POR）的女性。本研究显示，在周期取消率、每个启动周期回收的卵母细胞数量、受精率、每个启动周期获得的胚胎数量、着床率、临床妊娠率和活产率方面，均无统计学显著差异，尽管uHCG组每个启动周期的活产率（29.2%）是rLH组（8.0%）的3.6倍。需要进一步研究以验证在POR女性中，与rLH相比，补充uHCG是否能产生更好的临床结局。
